Journal profile · Medicine, Research & Experimental
EMBO Molecular Medicine
ISSN 1757-4676 · eISSN 1757-4684 · Wiley-Blackwell · ENGLAND · Monthly · Founded 2009
EMBO Molecular Medicine: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 7.86; fully open access; APC about USD 8,270; median 190 days to acceptance (101 articles, last 24 months); community-reported acceptance: fairly hard; 180 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
EMBO Molecular Medicine is published by Wiley-Blackwell and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Mitochondrial Function and Pathology, Immune Cell Function and Interaction and CRISPR and Genetic Engineering, together about 18.7% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
EMBO Molecular Medicine (EMM) publishes breakthrough research in translational and biomedical sciences in the field of experimental medicine. We welcome studies that deepen our understanding of human disease and provide mechanistic insight and translational implications in preclinical disease models and humans. Submissions with authoritative referee reports from Review Commons or other journals are welcome and will be considered, where possible, without additional review. The journal publishes research papers as full-length Articles, short Reports, Methods and Resource articles. In addition, EMM publishes Perspectives and Reviews that target a broad and non-specialised audience, as well as News & Views, Opinions, Correspondence and Comments. Areas covered include, but are not limited to: Ageing AI in medicine Biomarkers and Molecular diagnostics Biomedical technologies Dermatology Drug discovery Early-phase human clinical studies and case reports Endocrinology and Metabolic diseases Environmental health Exposome studies Gastroenterology Gene and cell therapy Human genetics, Autoimmunity, and Rare diseases Immunology and Inflammation Infectious diseases Microbiome Mitochondrial diseases Myopathies and Musculoskeletal diseases Nephrology Neurodegeneration and Neurological diseases Oncology Ophtalmology Reproductive medicine Respiratory diseases Stem cells and Regenerative medicine Systems medicine and Clinical omics Toxicology Vascular and cardiovascular diseases Vaccinology
From the journal's Aims & Scope
Research area (LetPub): Medicine, Research & Experimental
Editor-in-chief Philippe Sansonetti Collège dePublisher website
Editorial board by country: none in mainland China; most named United States 29, Germany 17, United Kingdom 9, France 9, Italy 8 (106 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Mitochondrial Function and PathologyBiochemistry, Genetics and Molecular Biology7.4%
- Immune Cell Function and InteractionImmunology and Microbiology5.8%
- CRISPR and Genetic EngineeringBiochemistry, Genetics and Molecular Biology5.5%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology5.2%
- Alzheimer's disease research and treatmentsMedicine4.9%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology4.5%
- Cancer Cells and MetastasisMedicine4.5%
- CAR-T cell therapy researchMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Medicine, Research & Experimental | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Medicine, Research & Experimental | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Medicine, Research & Experimental | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 7.86LetPub ·
- CiteScore 2026-06
- 13.1LetPub ·
- SJR 2026-06
- 3.28LetPub ·
- SNIP 2026-06
- 1.67LetPub ·
- h-index
- 90LetPub ·
- h-index
- 189OpenAlex ·
- i10-index
- 1,672OpenAlex ·
- 2-year mean citedness
- 7.24OpenAlex ·
- Self-citation rate
- 1.3%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 163LetPub ·
- Downloads per year (publisher) 2025
- 1,700,000Publisher website ·
Articles by year OpenAlex count · 2,431 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 158 | 158 | 122 |
| 2025 | 180 | 180 | 1,095 |
| 2024 | 171 | 171 | 2,466 |
| 2023 | 148 | 148 | 3,454 |
| 2022 | 131 | 131 | 4,716 |
| 2021 | 170 | 170 | 9,513 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
190 daysMedian, submission to acceptance · P25–P75 148 days – 287 days
- Acceptance to online
- median 22 days (101 articles)
- Submission to online
- median 217 days
- Sample
- 101 articles with submission and acceptance dates (131 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- Fairly hardLetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- Submission to publication (journal-reported)
- about 26 weeksDOAJ ·
- Peer review
- Double anonymous peer review, Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 7,028 / USD 8,270 / GBP 5,990 | Yes | CC BY, CC0 | |
| OpenAlex | USD 7,990 / EUR 6,790 / GBP 5,790 | — | — | |
| LetPub | EUR 6,490 / GBP 5,590 / USD 6,890 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Wiley-Blackwell
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 2009
- ISSN
- 1757-4676
- Electronic ISSN
- 1757-4684
- Latest issue on the website
- Volume 18, Issue 9 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about EMBO Molecular Medicine
What CAS zone is EMBO Molecular Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, EMBO Molecular Medicine is in Zone 1 of Medicine, and in Zone 1 of the minor category Medicine, Research & Experimental; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of EMBO Molecular Medicine?
The latest impact factor listed by LetPub is 7.86; CiteScore 13.1, h-index 189.
How long does peer review take at EMBO Molecular Medicine?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 190 days (interquartile range 148–287 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Fairly hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of EMBO Molecular Medicine based?
Of the 106 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (29), Germany (17) and United Kingdom (9). Counted from the institutions listed on the board page; for reference only.
Which databases index EMBO Molecular Medicine?
According to LetPub and DOAJ records, EMBO Molecular Medicine is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is EMBO Molecular Medicine open access, and what is the APC?
EMBO Molecular Medicine is a fully open-access journal. APC about USD 8,270.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .